부산대학교 도서관

ABSTRACT:: The use of amiodarone for post-operative atrial fibrillation is widespread; however, there is a paucity of data on the optimal duration of overlap when transitioning from intravenous to oral amiodarone. The objective of this study was to evaluate the safety and efficacy of varying durations of overlap when amiodarone intravenous infusion is transitioned to oral administration in cardiothoracic surgery patients. This retrospective, observational, single-center study included cardiothoracic surgery patients who were initiated on intravenous amiodarone for supraventricular arrhythmia and subsequently transitioned to oral amiodarone. The primary outcome was atrial fibrillation recurrence within 24 hours following intravenous amiodarone discontinuation. Safety outcomes include occurrence of bradycardia or hypotension while on amiodarone. A total of 184 patients were included for analysis. Atrial fibrillation recurrence occurred in 24.5% of patients (n = 45). No significant association was found between various overlap durations and atrial fibrillation recurrence (OR 1.00, 95% CI 1.00 to 1.01, P= 0.9). Additionally, no significant association was found between duration of overlap and rates of bradycardia (OR 1.00, 95% CI 0.99 to 1.00, P=0.08) or hypotension (OR 1.00, 95% CI 0.99 to 1.00, P=0.21), which occurred in 35.9% and 47.3% of patients respectively. Our study suggests following conversion to normal sinus rhythm, cardiothoracic surgery patients can effectively and safely be transitioned from intravenous to oral amiodarone without the need for specific overlap duration or transition strategy.